RenovoRx, Inc. Common Stock (RNXT) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with RNXT
Recent news

RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RNXT

RenovoRx Q2 Earnings Call Highlights
RenovoRx Q2 Earnings Call Highlights
RNXT

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RNXT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 36.88
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.01
- MACD histogram
- -0.05
- SMA 50
- $1.52
- Price below SMA 50
- EMA 50
- $1.49
- Price below EMA 50
- SMA 200
- $1.08
- Price above SMA 200
- EMA 200
- $1.18
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RNXT

RenovoRx Q2 Earnings Call Highlights
RenovoRx Q2 Earnings Call Highlights
RNXT

RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RNXT
News tone: automated (AI) classification of the article's content, not a price prediction.
About RenovoRx, Inc. Common Stock
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Ramtin Agah M.D. | Founder, Executive Chairman & Chief Medical Officer | 1966 |
| Mr. Shaun R. Bagai | CEO, Secretary & Director | 1977 |
| Mr. Ronald B. Kocak CPA, CGMA | VP of Finance & Controller | 1958 |
| Mr. Mark Voll | CFO & Principal Accounting Officer | 1955 |
| Mr. Tom Kelly | Vice President of Quality & Operations | — |
| Mr. Phil Stocton | Vice President of Sales & Market Development | — |
| Ms. Leesa Gentry | Chief Clinical Officer | 1970 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 36.88
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.01
- MACD histogram
- -0.05
- SMA 50
- $1.52
- Price below SMA 50
- EMA 50
- $1.49
- Price below EMA 50
- SMA 200
- $1.08
- Price above SMA 200
- EMA 200
- $1.18
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $14.50
- Average
- $14.50
- High
- $14.50
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +15.6 | -26.1 | -14.2 |



